Is SPHS or EQR a better dividend investment in 2026?

SPHS currently yields 200000000.00% with a 5% 5-year dividend growth rate. EQR yields 5.87% with 5% growth. The better choice depends on your goal: SPHS offers higher current income.

What is the dividend yield difference between SPHS and EQR?

SPHS has a forward dividend yield of 200000000.00% ($2.00/share annually). EQR yields 5.87% ($3.47/share annually). The yield gap is 199999994.13 percentage points.

Home › Compare › SPHS vs EQR

SPHS vs EQR: Dividend Comparison 2026

SPHS yields 200000000.00% · EQR yields 5.87%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SPHS wins by $4.875657285131069e+59M in total portfolio value

INVESTMENT

TIME HORIZON10 years

SPHS

● Live price

200000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.875657285131069e+59M

Annual income

$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00

Full SPHS calculator →

EQR

● Live price

5.87%

Share price

$59.15

Annual div

$3.47

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$47.8K

Annual income

$5,475.61

Full EQR calculator →

Portfolio growth — SPHS vs EQR

📍 SPHS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SPHS	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SPHS + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SPHS pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPHS

Annual income on $10K today (after 15% tax)

$17,000,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

EQR

Annual income on $10K today (after 15% tax)

$499.01/yr

After 10yr DRIP, annual income (after tax)

$4,654.27/yr

At 15% tax rate, SPHS beats the other by $414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPHS + EQR for your $10,000?

SPHS: 50%EQR: 50%

100% EQR50/50100% SPHS

Portfolio after 10yr

$2.4378286425655345e+59M

Annual income

$243,782,624,477,893,130,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

100.00%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

SPHS

Analyst Ratings

Buy

Consensus: Buy

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+18.9% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPHS buys

EQR buys

No recent congressional trades found for SPHS or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSPHSEQR

Forward yield	200000000.00% ✓	5.87%
Annual dividend / share	$2.00	$3.47 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$4.875657285131069e+59M	$47.8K ✓
Annual income after 10y	$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓	$5,475.61
Total dividends collected	$4.875656971401711e+59M	$23.0K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	REIT
Analyst consensus	Buy	Hold

Year-by-year: SPHS vs EQR ($10,000, DRIP)

Year	SPHS Portfolio	SPHS Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$20,000,010,700	$20,000,000,000.00	$11,380	$679.82	+$20000.00M → SPHS
2	$37,383,218,970,104,910	$37,383,197,570,093,464.00	$13,014	$837.25	+$37383218970.09M → SPHS
3	$65,303,942,472,059,150,000,000	$65,303,902,472,014,860,000,000.00	$14,961	$1,036.20	+$65303942472059152.00M → SPHS
4	$106,615,009,060,306,890,000,000,000,000	$106,614,939,185,088,440,000,000,000,000.00	$17,297	$1,289.22	+$1.0661500906030689e+23M → SPHS
5	$162,672,273,967,082,950,000,000,000,000,000,000	$162,672,159,889,023,270,000,000,000,000,000,000.00	$20,121	$1,613.15	+$1.6267227396708296e+29M → SPHS
6	$231,966,340,306,755,300,000,000,000,000,000,000,000,000	$231,966,166,247,422,140,000,000,000,000,000,000,000,000.00	$23,561	$2,030.84	+$2.319663403067553e+35M → SPHS
7	$309,138,182,305,146,600,000,000,000,000,000,000,000,000,000,000	$309,137,934,101,162,400,000,000,000,000,000,000,000,000,000,000.00	$27,783	$2,573.54	+$3.091381823051466e+41M → SPHS
8	$385,031,777,252,258,400,000,000,000,000,000,000,000,000,000,000,000,000	$385,031,446,474,403,340,000,000,000,000,000,000,000,000,000,000,000,000.00	$33,013	$3,284.39	+$3.850317772522584e+47M → SPHS
9	$448,184,411,799,345,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000	$448,183,999,815,344,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$39,547	$4,223.51	+$4.481844117993459e+53M → SPHS
10	$487,565,728,513,106,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000	$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$47,791	$5,475.61	+$4.875657285131069e+59M → SPHS

SPHS vs EQR: Complete Analysis 2026

SPHS — Stock

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Full SPHS Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this SPHS vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPHS vs SCHD SPHS vs JEPI SPHS vs O SPHS vs KO SPHS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.